{
      "Rank": 354,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [],
      "ArmGroupInterventionName": [
            "Drug: Cyclophosphamide",
            "Drug: Fludarabine",
            "Drug: Anti-thymocyte globulin",
            "Drug: Cyclosporine A",
            "Drug: Mycophenolate mofetil",
            "Procedure: Mesenchymal stem cell transplantation",
            "Radiation: Total body irradiation",
            "Procedure: Bone marrow or umbilical cord blood (UCG) stem cell transplantation"
      ],
      "ArmGroupLabel": [
            "Transplant in Epidermolysis Bullosa"
      ],
      "ArmGroupType": [
            "Experimental"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT01033552"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "This is an open-label, single institution, phase II study in patients with epidermolysis bullosa (EB). The underlying hypothesis is that the infusion of bone marrow or umbilical cord blood from a healthy unaffected donor will correct the collagen, laminin, integrin, or plakin deficiency and reduce the skin fragility characteristic of severe forms of EB. A secondary hypothesis is that mesenchymal stem cells from a healthy donor will enhance the safety and efficacy of the allogeneic hematopoietic stem cell transplant as well as serve as a source of renewable cells for the treatment of focal areas of residual blistering."
      ],
      "BriefTitle": [
            "Biochemical Correction of Severe EB by Allo HSCT and \"Off-the-shelf\" MSCs"
      ],
      "CentralContactEMail": [],
      "CentralContactName": [],
      "CentralContactPhone": [],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [],
      "CollaboratorClass": [],
      "CollaboratorName": [],
      "CompletionDate": [
            "December 12, 2022"
      ],
      "CompletionDateType": [
            "Anticipated"
      ],
      "Condition": [
            "Epidermolysis Bullosa"
      ],
      "ConditionAncestorId": [
            "D000012868",
            "D000000013",
            "D000012873",
            "D000030342",
            "D000012871",
            "D000012872"
      ],
      "ConditionAncestorTerm": [
            "Skin Abnormalities",
            "Congenital Abnormalities",
            "Skin Diseases, Genetic",
            "Genetic Diseases, Inborn",
            "Skin Diseases",
            "Skin Diseases, Vesiculobullous"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC16",
            "BC17",
            "All",
            "Rare"
      ],
      "ConditionBrowseBranchName": [
            "Diseases and Abnormalities at or Before Birth",
            "Skin and Connective Tissue Diseases",
            "All Conditions",
            "Rare Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Epidermolysis Bullosa",
            "Epidermolysis Bullosa"
      ],
      "ConditionBrowseLeafId": [
            "M7128",
            "M12",
            "M14824",
            "M14826",
            "M14828",
            "M22839",
            "M14827",
            "T2098"
      ],
      "ConditionBrowseLeafName": [
            "Epidermolysis Bullosa",
            "Congenital Abnormalities",
            "Skin Abnormalities",
            "Skin Diseases",
            "Skin Diseases, Genetic",
            "Genetic Diseases, Inborn",
            "Skin Diseases, Vesiculobullous",
            "Epidermolysis Bullosa"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "high"
      ],
      "ConditionMeshId": [
            "D000004820"
      ],
      "ConditionMeshTerm": [
            "Epidermolysis Bullosa"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "N/A"
      ],
      "DesignInterventionModel": [
            "Single Group Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "None (Open Label)"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [],
      "DetailedDescription": [
            "The primary objective of this study is to estimate the event-free survival rate by 1 year post-transplant with an event defined as a death or failure to have a demonstrable increase in collagen, laminin, integrin, keratin or plakin deposition by 1 year post-transplant or other biochemical, structural or physical measure of improvement.\n\nThe secondary objectives of this study are to i) determine the incidence of transplant-related mortality (TRM) at 180 days; ii) describe the pattern of biochemical improvement as measured by an increase in protein expression (collagen, laminin, integrin, keratin or plakin) and related structural and physical changes; iii) describe health quality of life at day 365 and 730 as compared to pretreatment results; iv) describe the pattern and durability of HSC and third party MSC engraftment in the skin; v) determine the probability of survival at 1 year.\n\nPatients with severe epidermolysis bullosa will be screened to meet the eligibility requirements, related or unrelated donor marrow or UCB will be infused, and subjects will be followed for a minimum of 5 years after stem cell transplant. A target accrual of 75 subjects over 5 years will be recruited to the study."
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nDiagnosis of severe form of epidermolysis bullosa (EB) characterized by collagen, laminin, integrin, keratin or plakin deficiency. Assessment criteria for severe EB:\n\nDocumented collagen, laminin, integrin, keratin or plakin deficiency (by immunofluorescence staining with protein specific antibodies or Western blotting and by mutation analysis)\n\nAdequate Organ Function Criteria\n\nRenal: glomerular filtration rate within normal range for age\nHepatic: bilirubin, aspartate aminotransferase/alanine aminotransferase (AST/ALT), Alkaline phosphatase (ALP) < 5 x upper limit of normal\nPulmonary: adequate pulmonary function in the opinion of the enrolling investigator\nCardiac: left ventricular ejection fraction \u2265 45%, normal electrocardiogram (EKG) or approved by Cardiology for transplant.\n\nAvailable Healthy HSC Donor (order of preference)\n\nRelated Donor (marrow or UCB)\n\nHLA-A, B, C, DRB1 genotypic identical (sibling) donor\nHLA-A, B, C, DRB1 phenotypic identical donor\n7/8 HLA matched donor at HLA-A, B, C, DRB1\n\nUnrelated Donor\n\nMarrow\n\nHLA-A, B, C, DRB1 phenotypic identical donor\n7/8 HLA matched donor at HLA-A, B, C, DRB1\n\nUCB\n\nHLA-A, B (antigen level) and DRB1 (allele level) matched donor\n5/6 HLA matched donor at HLA-A, B, DRB1\n4/6 HLA matched donor at HLA-A, B, DRB1\nVoluntary written consent\n\nAbsence of Exclusion Criteria:\n\nActive systemic infection at time of transplantation (including active infection with Aspergillus or other mold within 30 days).\nHistory of human immunodeficiency virus (HIV) infection\nEvidence of squamous cell carcinoma\nDonor has EB\nPregnancy females of child-bearing age must have a documented negative pregnancy test and agree to use contraception as a condition for enrollment."
      ],
      "EnrollmentCount": [
            "32"
      ],
      "EnrollmentType": [
            "Actual"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [
            "D000007166",
            "D000007155",
            "D000045505",
            "D000018501",
            "D000018906",
            "D000000477",
            "D000045504",
            "D000000970",
            "D000019653",
            "D000004791",
            "D000000935",
            "D000000890",
            "D000003879",
            "D000065095",
            "D000000903",
            "D000000904",
            "D000000995",
            "D000000900"
      ],
      "InterventionAncestorTerm": [
            "Immunosuppressive Agents",
            "Immunologic Factors",
            "Physiological Effects of Drugs",
            "Antirheumatic Agents",
            "Antineoplastic Agents, Alkylating",
            "Alkylating Agents",
            "Molecular Mechanisms of Pharmacological Action",
            "Antineoplastic Agents",
            "Myeloablative Agonists",
            "Enzyme Inhibitors",
            "Antifungal Agents",
            "Anti-Infective Agents",
            "Dermatologic Agents",
            "Calcineurin Inhibitors",
            "Antibiotics, Antineoplastic",
            "Antibiotics, Antitubercular",
            "Antitubercular Agents",
            "Anti-Bacterial Agents"
      ],
      "InterventionArmGroupLabel": [
            "Transplant in Epidermolysis Bullosa",
            "Transplant in Epidermolysis Bullosa",
            "Transplant in Epidermolysis Bullosa",
            "Transplant in Epidermolysis Bullosa",
            "Transplant in Epidermolysis Bullosa",
            "Transplant in Epidermolysis Bullosa",
            "Transplant in Epidermolysis Bullosa",
            "Transplant in Epidermolysis Bullosa"
      ],
      "InterventionBrowseBranchAbbrev": [
            "Infe",
            "ARhu",
            "Derm",
            "All",
            "ANeo",
            "CNSDep",
            "Ot"
      ],
      "InterventionBrowseBranchName": [
            "Anti-Infective Agents",
            "Antirheumatic Agents",
            "Dermatologic Agents",
            "All Drugs and Chemicals",
            "Antineoplastic Agents",
            "Central Nervous System Depressants",
            "Other Dietary Supplements"
      ],
      "InterventionBrowseLeafAsFound": [
            "Impact",
            "Impact",
            "Bolus",
            "Under",
            "Tablet",
            "Training program"
      ],
      "InterventionBrowseLeafId": [
            "M18113",
            "M5882",
            "M11280",
            "M283219",
            "M5879",
            "M4006",
            "M225481",
            "M3431",
            "M9364",
            "M9353",
            "M19757",
            "M20095",
            "M2972",
            "M3406",
            "M5404",
            "M10948",
            "M3366",
            "M6226",
            "M29605",
            "M3374",
            "M3376",
            "M3463",
            "T433"
      ],
      "InterventionBrowseLeafName": [
            "Cyclosporine",
            "Cyclosporins",
            "Mycophenolic Acid",
            "Fludarabine",
            "Cyclophosphamide",
            "Benzocaine",
            "Fludarabine phosphate",
            "Antilymphocyte Serum",
            "Immunosuppressive Agents",
            "Immunologic Factors",
            "Antirheumatic Agents",
            "Antineoplastic Agents, Alkylating",
            "Alkylating Agents",
            "Antifungal Agents",
            "Clotrimazole",
            "Miconazole",
            "Anti-Infective Agents",
            "Dermatologic Agents",
            "Calcineurin Inhibitors",
            "Anti-Bacterial Agents",
            "Antibiotics, Antitubercular",
            "Antitubercular Agents",
            "Tannic Acid"
      ],
      "InterventionBrowseLeafRelevance": [
            "high",
            "high",
            "high",
            "high",
            "high",
            "low",
            "low",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low"
      ],
      "InterventionDescription": [
            "Cyclophosphamide 50 mg/kg/day IV over 2 hours x 1 day, total dose 50 mg/kg will be administered on Day -6.",
            "40 mg/m^2/day intravenously on Days -6, -5, -4, -3 and -2.",
            "30 mg/kg on Days -4, -3 and -2.",
            "Days -3 to 100+ to maintain a level of >200 ng/ml; initial dose 2.5 mg/kg over 2 hours every 8-12 hours for children.",
            "15 mg/kg intravenous twice per day on days -3 through 30.",
            "infused via intravenous drip on Day 0",
            "300 cGY on Day -1 administered in a single fraction at a dose rate of 10-19 cGy/minute prescribed to the midplane of the patient at the level of the umbilicus.",
            "Bone marrow or UCB products will be infused as soon as the product arrives and within 30 minutes. The product is infused via IV drip."
      ],
      "InterventionMeshId": [
            "D000016572",
            "D000009173",
            "D000003520",
            "C000024352",
            "D000003524",
            "D000000961"
      ],
      "InterventionMeshTerm": [
            "Cyclosporine",
            "Mycophenolic Acid",
            "Cyclophosphamide",
            "Fludarabine",
            "Cyclosporins",
            "Antilymphocyte Serum"
      ],
      "InterventionName": [
            "Cyclophosphamide",
            "Fludarabine",
            "Anti-thymocyte globulin",
            "Cyclosporine A",
            "Mycophenolate mofetil",
            "Mesenchymal stem cell transplantation",
            "Total body irradiation",
            "Bone marrow or umbilical cord blood (UCG) stem cell transplantation"
      ],
      "InterventionOtherName": [
            "Cytoxan",
            "Fludara",
            "ATG",
            "CSA",
            "CellCept(R)",
            "MSCT",
            "UCBSCT"
      ],
      "InterventionType": [
            "Drug",
            "Drug",
            "Drug",
            "Drug",
            "Drug",
            "Procedure",
            "Radiation",
            "Procedure"
      ],
      "IsFDARegulatedDevice": [],
      "IsFDARegulatedDrug": [
            "Yes"
      ],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "September 29, 2022"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "September 28, 2022"
      ],
      "LeadSponsorClass": [
            "OTHER"
      ],
      "LeadSponsorName": [
            "Masonic Cancer Center, University of Minnesota"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Minneapolis"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [
            "United States"
      ],
      "LocationFacility": [
            "University of Minnesota Masonic Cancer Center and Medical Center"
      ],
      "LocationState": [
            "Minnesota"
      ],
      "LocationStatus": [],
      "LocationZip": [
            "55455"
      ],
      "MaximumAge": [
            "25 Years"
      ],
      "MinimumAge": [],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "MT2009-09: Biochemical Correction of Severe Epidermolysis Bullosa by Allogeneic Stem Cell Transplantation and \"Off-the-shelf\" Mesenchymal Stem Cells"
      ],
      "OrgClass": [
            "OTHER"
      ],
      "OrgFullName": [
            "Masonic Cancer Center, University of Minnesota"
      ],
      "OrgStudyId": [
            "MT2009-09"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Masonic Cancer Center, University of Minnesota"
      ],
      "OverallOfficialName": [
            "Jakub Tolar, MD, PhD"
      ],
      "OverallOfficialRole": [
            "Principal Investigator"
      ],
      "OverallStatus": [
            "Active, not recruiting"
      ],
      "OversightHasDMC": [
            "Yes"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 1",
            "Phase 2"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "November 12, 2022"
      ],
      "PrimaryCompletionDateType": [
            "Anticipated"
      ],
      "PrimaryOutcomeDescription": [
            "Event-free survival rate, with an event defined as death or failure to have a demonstrable increase in collagen, laminin, intergrin, keratin or plakin deposition."
      ],
      "PrimaryOutcomeMeasure": [
            "Event-free survival rate"
      ],
      "PrimaryOutcomeTimeFrame": [
            "1 year and 2 Years Post-transplant"
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [
            "0911M74035"
      ],
      "SecondaryIdDomain": [
            "IRB, University of Minnesota"
      ],
      "SecondaryIdLink": [],
      "SecondaryIdType": [
            "Other Identifier"
      ],
      "SecondaryOutcomeDescription": [
            "Incidence of transplant-related mortality (TRM)",
            "Describe pattern of biochemical improvement as measured by an increase in protein expression (collagen, laminin, integrin, keratin, or plakin) and related structural and physical changes",
            "Health quality of life questionnaire or iscorEB as compared to pretreatment results",
            "Incidence of HSC and third party MSC engraftment in the skin",
            "Number of surviving patients one year after engraftment",
            "Incidence of acute GCHD"
      ],
      "SecondaryOutcomeMeasure": [
            "Transplant-related mortality (TRM)",
            "Pattern of biochemical improvement",
            "Measure patients Quality of Life using a questionnaire",
            "Durability of HSC and third party MSC engraftment in the skin",
            "Probability of Survival",
            "Number of participants experiencing Acute GVHD"
      ],
      "SecondaryOutcomeTimeFrame": [
            "180 Days Post Transplant",
            "Through 1 Year Post-Transplant",
            "Pretreatment, Day 100, 6 months, 1 and 2 years",
            "100 Days",
            "1 Year",
            "100 Days"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "January 2010"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "September 2022"
      ],
      "StdAge": [
            "Child",
            "Adult"
      ],
      "StudyFirstPostDate": [
            "December 16, 2009"
      ],
      "StudyFirstPostDateType": [
            "Estimate"
      ],
      "StudyFirstSubmitDate": [
            "December 14, 2009"
      ],
      "StudyFirstSubmitQCDate": [
            "December 14, 2009"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}